All News

RheumNow Podcast square

CBT or Naltrexone in Fibromyalgia (12.8.2023)

d Jack Cush, MD

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.  Be sure to catch the early registration break for 2024 RheumNow Live.

Read Article
ICYMI: New Biomarkers and Therapeutics Show Potential in Still's Disease AOSD is a rare complex, sporadic, systemic autoinflammatory disease similar to sJIA characterized by sustained fever, salmon-colored rash, and arthritis . https://t.co/ZU0XFecPyP https://t.co/GLPsf73Hj0

Links:

Dr. John Cush RheumNow ( View Tweet)

Polands disease study (sarcoidosis 78.6K; #AOSD 3294; systemic sclerosis 35.5K) betw 2009-2018. Avg hospitalization was 5.39 days sarcoidosis, 6.22 days scleroderma, & 7.44 days for Still’s (latter decr 11.7 to 5.8, betw 2008-2014) https://t.co/OcNzt7IKC5 https://t.co/uPcbOyizQN

Links:

Dr. John Cush RheumNow ( View Tweet)
Stills,continuum

ICYMI: New Biomarkers and Therapeutics Show Potential in Still's Disease

d Bella Mehta, MBBS, MS

Adult-onset Still’s disease is a rare complex, sporadic, systemic autoinflammatory disease similar to systemic juvenile idiopathic arthritis characterized by sustained fever, salmon-colored rash, and arthritis. The 2023 ACR convergence featured several abstracts spotlighting developments in understanding and managing this complex disease spectrum.

Read Article

NEW Health Policy—Diagnosis and investigation of suspected haemophagocytic lymphohistiocytosis in adults: 2023 Hyperinflammation and HLH Across Speciality Collaboration (HiHASC) consensus guideline https://t.co/WYNcVigb7n Free to read with registration on https://t.co/28wkm59DgB https://t.co/Qbm1y76o3E

The Lancet Rheumatology TheLancetRheum ( View Tweet)
Hemophagocytic Lymphohistiocytosis in Still's Disease Dr. Bella Mehta discusses abstract 1143 presented at the 2023 ACR Convergence meeting in San Diego, CA. https://t.co/bFeGK6MTcc https://t.co/cxJg6rQ7gm

Links:

Dr. John Cush RheumNow ( View Tweet)
New Biomarkers and Therapeutics Show Potential in Still's Disease AOSD is a rare complex, sporadic, systemic autoinflammatory disease similar to sJIA characterized by sustained fever, salmon-colored rash, and arthritis https://t.co/cGBBHsBdK7 https://t.co/a0EwBiTJSu

Links:

Dr. John Cush RheumNow ( View Tweet)
rare

Here at Last: Treatment Options for VEXAS

d Michael Putman, MD, MSCI

We have known about the VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome for nearly 3 years, but there has been relatively little to say about how to treat it. To date there have been over twice as many publications about VEXAS (263 publications) as there have been patients described with respect to treatment strategies (116 patients). One of the late breaking abstracts may finally have rectified this imbalance.

Read Article
Systematic review and meta-analysis of efficacy and and safety or therapies in Adult Onset Still's Disease and sJIA IL-1i and IL-6i - highest evidence for treatment Early (<3 months) intervention = higher rate of dz inactivity @RheumNow #ACR23 Abs#2569 https://t.co/XzzwbLFpo7
Robert B Chao, MD  ( View Tweet)
Stills,continuum

New Biomarkers and Therapeutics Show Potential in Still's Disease

d Bella Mehta, MBBS, MS

Adult-onset Still’s disease (AOSD) is a rare complex, sporadic, systemic autoinflammatory disease similar to systemic juvenile idiopathic arthritis (sJIA) characterized by sustained fever, salmon-colored rash, and arthritis.

Read Article
TM61 at #ACR23 23 yo M p/w ~3mo of sternal swelling - US probable abscess, drained + multiple abx w/ no improvement - XR R shoulder + L elbow nl but MRI abn - MRI L elbow: possible osteomyelitis (OM) - MRI R shoulder; clavicular osteolysis - Bone Bx clavicle + L Ulna: Chronic… https://t.co/7s9PIwByTs https://t.co/wKaKfnncP5
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
https://t.co/ft1wNmMxGx

Links:

Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
#VEXAS is still hot at #ACR23 - 245K whole genome sequencing data from #NIH All of US - 74 with somatic mutation UBA1 Increased asthma, Tietze’s syndrome and neutropenia Hemoglobin similar in cases and controls @rheumnow #abstL03 https://t.co/A374w60e6H
Bella Mehta bella_mehta ( View Tweet)
How do we treat #VEXAS - UBA1 mutation Large multicenter cohort - 110 pts, 99% M Confirms the benefit of JAKi and tocilizumab Others not so much @RheumNow #ACR23 #ACRBest #abstL03 https://t.co/tRjO31IHiD
Bella Mehta bella_mehta ( View Tweet)
Defining accuracy of Administrative Codes for Autoinflammatory Syndromes is important to lay groundwork! AOSD, SJIA, BD, FMF, CAPS and SAPHO-CNO ICD codes validated as Autoinflammatory syndromes (AIS)- PPV low @RheumNow #ACR23 #abst1129 https://t.co/XqIrUmUCVc
Bella Mehta bella_mehta ( View Tweet)
Nationwide analysis of #AOSD pts with and without #HLH - HLH Much higher in Hispanics Much more in younger pts Abst1143 @rheumnow #ACR23 https://t.co/fluZ4X2HHi
Bella Mehta bella_mehta ( View Tweet)
Assessment of MAP kinase pathway gene expression prior to tx may aid in identification of polyarticular course JIA patients that could exhibit poor response to tofacitinib. It may be helpful in personalized tx algorithm! #ACR23 Abs #0830 https://t.co/Z8pykbG7x5 @rheumnow https://t.co/ANZr8aVrVB
Dr. Rachel Tate  ( View Tweet)
STOP-JIA study data from Abs #0831 suggest improved effectiveness with early combination tx vs step up and biologic first tx at the 2-3 yr timeframe for pJIA pts. More data needed to optimize outcomes/tx for these children. https://t.co/vWL5J4FPbo #ACR23 @rheumnow https://t.co/5iJpwglhPu
Dr. Rachel Tate  ( View Tweet)
Efficacy and Safety of Targeted Therapies in #VEXAS Syndrome: Retrospective Study from the French VEXAS Group :) #ACR23 late breaking poster - the figure says it all https://t.co/qahDDPLois https://t.co/ueb4aG8t77
Latika LatikaGupta_ ( View Tweet)
Is there a difference in secukinumab vs. adalimumab biosimilar on radiographic progression in a subgroup of axSpA pts with syndesmophytes or CRP levels? Radiographic progression equally low in both drugs NO difference in syndesmophytes or CRP @RheumNow #ACR23 Abs#0522 https://t.co/1TBKAxuKPE
Robert B Chao, MD  ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright {{ 'now'|date('Y') }} All Rights Reserved.